Adcom puts up a Blenrep roadblock
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
A surprising no to both multiple myeloma uses puts the ball in the FDA's court.
A newly published cache of CRLs includes six novel oncology drugs.
Autogene cevumeran goes on hold in adjuvant bladder cancer.
Zegfrovy is approved in a best-case setting, but Dizal has no US presence.
Lynozyfic could have an edge over rival BCMA-targeting bispecifics.
Satri-cel is filed for gastric cancer approval in China.
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.